Literature DB >> 26496429

Influence of molecular size on tissue distribution of antibody fragments.

Zhe Li1,2, Ben-Fillippo Krippendorff3,2, Sharad Sharma1, Antje C Walz3, Thierry Lavé4, Dhaval K Shah1.   

Abstract

Biodistribution coefficients (BC) allow estimation of the tissue concentrations of proteins based on the plasma pharmacokinetics. We have previously established the BC values for monoclonal antibodies. Here, this concept is extended by development of a relationship between protein size and BC values. The relationship was built by deriving the BC values for various antibody fragments of known molecular weight from published biodistribution studies. We found that there exists a simple exponential relationship between molecular weight and BC values that allows the prediction of tissue distribution of proteins based on molecular weight alone. The relationship was validated by a priori predicting BC values of 4 antibody fragments that were not used in building the relationship. The relationship was also used to derive BC50 values for all the tissues, which is the molecular weight increase that would result in 50% reduction in tissue uptake of a protein. The BC50 values for most tissues were found to be ~35 kDa. An ability to estimate tissue distribution of antibody fragments based on the BC vs. molecular size relationship established here may allow better understanding of the biologics concentrations in tissues responsible for efficacy or toxicity. This relationship can also be applied for rational development of new biotherapeutic modalities with optimal biodistribution properties to target (or avoid) specific tissues.

Entities:  

Keywords:  Antibody Fragments; Biodistribution Coefficient (BC); Biologics; Monoclonal Antibody (mAb); PBPK Model; QSPKR; Tissue Distribution

Mesh:

Substances:

Year:  2015        PMID: 26496429      PMCID: PMC5040103          DOI: 10.1080/19420862.2015.1111497

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  16 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.

Authors:  K Sandström; A K Haylock; D Spiegelberg; F Qvarnström; K Wester; M Nestor
Journal:  Int J Oncol       Date:  2012-02-01       Impact factor: 5.650

Review 3.  Transport of macromolecules across microvascular walls: the two-pore theory.

Authors:  B Rippe; B Haraldsson
Journal:  Physiol Rev       Date:  1994-01       Impact factor: 37.312

Review 4.  Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.

Authors:  Robert A Beckman; Louis M Weiner; Hugh M Davis
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

Review 5.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.

Authors:  Daniele Venturoli; Bengt Rippe
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

6.  Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.

Authors:  Hao Hong; Yin Zhang; Hakan Orbay; Hector F Valdovinos; Tapas R Nayak; Jero Bean; Charles P Theuer; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2013-01-14       Impact factor: 4.939

7.  Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  MAbs       Date:  2013-02-13       Impact factor: 5.857

8.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

Authors:  Michael M Schmidt; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

9.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

10.  Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability.

Authors:  Hemant Sarin
Journal:  J Angiogenes Res       Date:  2010-08-11
View more
  36 in total

1.  Antibody pharmacokinetics in rat brain determined using microdialysis.

Authors:  Hsueh-Yuan Chang; Kasey Morrow; Emily Bonacquisti; WanYing Zhang; Dhaval K Shah
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

2.  Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.

Authors:  Romany Abskharon; Paul M Seidler; Michael R Sawaya; Duilio Cascio; Tianxiao P Yang; Stephan Philipp; Christopher Kazu Williams; Kathy L Newell; Bernardino Ghetti; Michael A DeTure; Dennis W Dickson; Harry V Vinters; Philip L Felgner; Rie Nakajima; Charles G Glabe; David S Eisenberg
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

3.  Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.

Authors:  Zhe Li; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-26       Impact factor: 2.745

4.  Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease.

Authors:  Matthias Vandesquille; Tengfei Li; Chrystelle Po; Christelle Ganneau; Pascal Lenormand; Clémence Dudeffant; Christian Czech; Fiona Grueninger; Charles Duyckaerts; Benoît Delatour; Marc Dhenain; Pierre Lafaye; Sylvie Bay
Journal:  MAbs       Date:  2017-06-28       Impact factor: 5.857

Review 5.  Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Drug Metab Pharmacokinet       Date:  2018-11-22       Impact factor: 3.614

6.  Influence of Molecular size on the clearance of antibody fragments.

Authors:  Zhe Li; Ben-Fillippo Krippendorff; Dhaval K Shah
Journal:  Pharm Res       Date:  2017-07-05       Impact factor: 4.200

7.  Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.

Authors:  Cornelius Cilliers; Hans Guo; Jianshan Liao; Nikolas Christodolu; Greg M Thurber
Journal:  AAPS J       Date:  2016-06-10       Impact factor: 4.009

8.  Effect of Size on Solid Tumor Disposition of Protein Therapeutics.

Authors:  Zhe Li; Yingyi Li; Hsuan-Ping Chang; Hsueh-Yuan Chang; Leiming Guo; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2019-08-06       Impact factor: 3.922

Review 9.  Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.

Authors:  Mariam Elshiaty; Hannah Schindler; Petros Christopoulos
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 10.  Strategies for Site-Specific Labeling of Receptor Proteins on the Surfaces of Living Cells by Using Genetically Encoded Peptide Tags.

Authors:  Philipp Wolf; Georgina Gavins; Annette G Beck-Sickinger; Oliver Seitz
Journal:  Chembiochem       Date:  2021-02-26       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.